Elzanowska Julia, Berrocal Laura, García-Peláez Beatriz, Vives-Usano Marta, Sebo Beatriz Passos, Maia Joana, Batista Silvia, Teppo Jaakko, Varjosalo Markku, Moraes Maria Carolina Strano, Molina-Vila Miguel Ángel, Costa-Silva Bruno
Champalimaud Physiology and Cancer Programme, Champalimaud Foundation, 1400-038 Lisbon, Portugal.
Laboratorio de Oncología/Pangaea Oncology, Hospital Universitario Quirón-Dexeus, 08028 Barcelona, Spain.
Cancers (Basel). 2022 Jul 2;14(13):3258. doi: 10.3390/cancers14133258.
(1) Background: Extracellular vesicles (EVs) have emerged as crucial players in the communication between cells in both physiological and pathological scenarios. The functions of EVs are strongly determined by their molecular content, which includes all bioactive molecules, such as proteins, lipids, RNA, and, as more recently described, double-stranded DNA. It has been shown that in oncological settings DNA associated with EVs (EV-DNA) is representative of the genome of parental cells and that it reflects the mutational status of the tumor, gaining much attention as a promising source of biomarker mutant DNA. However, one of the challenges in studies of EV-DNA is the lack of standardization of protocols for the DNA extraction from EVs, as well as ways to assess quality control, which hinders its future implementation in clinics. (2) Methods: We performed a comprehensive comparison of commonly used approaches for EV-DNA extraction by assessing DNA quantity, quality, and suitability for downstream analyses. (3) Results: We here established strategic points to consider for EV-DNA preparation for mutational analyses, including qPCR and NGS. (4) Conclusions: We put in place a workflow that can be applied for the detection of clinically relevant mutations in the EV-DNA of cancer patients.
(1) 背景:细胞外囊泡(EVs)已成为生理和病理情况下细胞间通讯的关键参与者。EVs的功能很大程度上由其分子内容物决定,这些分子内容物包括所有生物活性分子,如蛋白质、脂质、RNA,以及最近发现的双链DNA。研究表明,在肿瘤学环境中,与EVs相关的DNA(EV-DNA)代表亲代细胞的基因组,反映肿瘤的突变状态,作为一种有前景的生物标志物突变DNA来源备受关注。然而,EV-DNA研究面临的挑战之一是缺乏从EVs中提取DNA的标准化方案以及质量控制方法,这阻碍了其在临床中的未来应用。(2) 方法:我们通过评估DNA数量、质量以及对下游分析的适用性,对常用的EV-DNA提取方法进行了全面比较。(3) 结果:我们在此确定了用于突变分析的EV-DNA制备需考虑的关键点,包括定量聚合酶链反应(qPCR)和二代测序(NGS)。(4) 结论:我们建立了一个可用于检测癌症患者EV-DNA中临床相关突变的工作流程。